SEC Filing Summary: AmerisourceBergen Corporation (10-Q)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2009. The registrant is AmerisourceBergen Corporation (Note: The input metadata references "Cencora," but the filing text explicitly identifies the company as AmerisourceBergen Corporation). The company operates as a pharmaceutical services provider with three operating segments aggregated into one reportable segment: Pharmaceutical Distribution. This segment includes AmerisourceBergen Drug Corporation (ABDC), the AmerisourceBergen Specialty Group (ABSG), and the AmerisourceBergen Packaging Group (ABPG).
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2009 | Six Months Ended Mar 31, 2009 |
|---|---|---|
| Total Revenue | $17.31 Billion | $34.65 Billion |
| Gross Profit | $552.5 Million (3.19% margin) | $1.04 Billion (3.01% margin) |
| Operating Income | $248.3 Million (1.43% margin) | $446.2 Million (1.29% margin) |
| Net Income | $143.4 Million | $254.4 Million |
| Diluted EPS (Continuing Ops) | $0.95 | $1.67 |
| Cash and Cash Equivalents | $655.3 Million (as of Mar 31, 2009) | |
| Total Debt | $1.16 Billion (including current portion) | |
| Operating Cash Flow (6 months) | $32.4 Million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 2.5% in the quarter and 1.1% in the six-month period compared to the prior year. This was primarily driven by the loss of a national retail drug chain customer (approx. $3.0 billion annualized impact) and one fewer business day in the quarter.
- Profitability Growth: Despite revenue declines, Operating Income increased 5.6% (quarter) and 4.3% (six months). Gross profit margins expanded by 16 basis points (quarter) and 9 basis points (six months) due to strong growth in generic programs and fee-for-service agreements.
- Segment Performance: ABDC revenue declined 4% (quarter) and 2% (six months) due to the lost customer. Conversely, ABSG revenue grew 8% (quarter) and 7% (six months), driven by oncology and specialty distribution, though offset by a 30% decline in oncology-related anemia drug sales due to regulatory and reimbursement changes.
- Costs: Operating expenses remained relatively flat despite increased spending on a Business Transformation (ERP) project, offset by productivity improvements and the "cE2" cost-reduction initiative. Facility consolidation and severance charges increased to $4.3 million (quarter) and $5.3 million (six months).
- Discontinued Operations: The company completed the divestiture of its workers' compensation business (PMSI) in October 2008. Results are classified as discontinued operations.
Guidance, Outlook, and Risks
- Guidance: Management expects total revenue growth for fiscal 2009 to be between 1% and 3%. ABDC is expected to grow 0% to 2%, while ABSG is expected to grow 5% to 7%. Second-half growth is anticipated to be higher for ABDC as the impact of the lost customer base normalizes.
- Capital Allocation: The company has a $500 million share repurchase program authorized in November 2008. As of March 31, 2009, approximately $338.3 million remained available. The quarterly dividend was increased by 33% to $0.10 per share in November 2008.
- Liquidity: The company maintains a $695 million multi-currency revolving credit facility and a $975 million receivables securitization facility (amended in April 2009 to reduce capacity to $700 million and extend maturity). Borrowing rates increased in April 2009 due to credit market conditions.
- Risks and Contingencies:
- Legal Matters: The company is involved in the "Bergen Brunswig Matter," accruing an additional $2.2 million in the quarter. It also faces a civil rebate payment order from the Ontario Ministry of Health (C$5.8 million) and a related civil complaint.
- Regulatory/Market: Continued decline in anemia drug sales due to FDA warnings and CMS reimbursement policy reviews. Potential impact of healthcare reform legislation, including the proposed elimination of LIFO accounting.
- IT Implementation: Risks associated with the implementation of a new enterprise resource planning (ERP) system.
Investor Verification Checklist
- Verify the impact of the lost national retail drug chain customer on future revenue stability and the timeline for new customer acquisitions to offset this loss.
- Monitor the trajectory of anemia drug sales and the potential for further regulatory restrictions or reimbursement cuts affecting the ABSG segment.
- Review the status of the "Bergen Brunswig Matter" litigation and the Ontario Ministry of Health rebate order for potential additional liabilities.
- Assess the progress and cost overruns of the Business Transformation (ERP) project and its impact on operating expenses.
- Confirm the company's ability to maintain liquidity given the increased borrowing costs and reduced availability under credit facilities following the Lehman Brothers bankruptcy impact.